January 25, 2012 — Terumo Cardiovascular Systems announced today that it has entered into an exclusive agreement with LAAx Inc. to distribute the TigerPaw System II, a left atrial appendage (LAA) closure device in the United States.
January 25, 2012 — Physicians at University Hospitals (UH) Case Medical Center enrolled their first patient in LEVANT 2, a global, multicenter, randomized clinical trial evaluating the safety and efficacy of the Moxy drug-coated balloon for the treatment of peripheral arterial disease (PAD).
January 25, 2012 — Rhode Island Hospital is the first hospital in the world to acquire the BodyTom portable, intra-operative, multi-slice computed tomography (CT) body scanner.
January 25, 2012 — Philips Healthcare announced the release of the Xper Flex Cardio Physiomonitoring system, a hemodynamic cardiac monitoring solution used to facilitate invasive investigation of heart and vascular disease.
January 23, 2012 – Boston Scientific Corp. said the U.S. District Court for the District of New Jersey has found all the asserted patents for a coronary stent in a lawsuit brought by Johnson & Johnson to be invalid and entered judgment in favor of Boston Scientific.
The next big advancement in cardiac imaging is likely to be computed tomography (CT) perfusion imaging. This enables one commonly available modality to image both the detailed anatomy and function of the heart at the same time. The impact on medicine could reduce healthcare costs by eliminating some hospital stays, cutting the number of tests and speeding patient diagnosis.
If you enjoy this content, please share it with a colleague
January 23, 2012 — CardioComm Solutions, Inc. a provider of ECG acquisition and management software solutions, received clearance from the U.S. Food and Drug Administration (FDA) for over-the-counter (OTC) sales and marketing of their consumer-based, hand-held heart rhythm monitor known as the HeartCheck Pen Handheld ECG.
January 23, 2012 — A collection of real-life data from 5,000 atrial fibrillation (AF) patients across seven countries will generate invaluable insights into one of Europe's leading causes of stroke. Daiichi Sankyo Europe GmbH today announced the enrolment of the first patient into the Prevention of thromboembolic events - European Registry in Atrial Fibrillation (PREFER in AF).